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creativecommons.org/licenses/by-nc-Summary Background: A main cause of hepatitis A and B infections in European countries is
travel to endemic countries. Most research on hepatitis vaccination among travellers from Eur-
ope has been conducted in airports or travel clinics, samples which potentially overrepre-
sented frequent travellers.
Methods: 2102 respondents across France, Germany, Italy, Spain, and UK completed an
internet-based questionnaire. Vaccination status, travel to endemic countries, and other
characteristics were compared across frequent, occasional, and non-travellers. Logistic re-
gressions tested association between vaccination and travel adjusting for potential con-
founders.
Results: Most respondents were occasional travellers (61%) and 24% were frequent travel-
lers. Frequent travellers had 2.3e2.4 times the odds of being vaccinated relative to non-
travellers, and odds of vaccination were 2.5e3.1 times higher among travellers to endemic
areas relative to others (all p < .05). Frequent travellers were more aware of their vacci-
nation status (HAV: 80% vs. 72%; HBV: 82% vs. 74%), though many who were vaccinated
could not identify the number of injections to complete the series (47% vs. 29%) (all
p < .05).; HBV, Hepatitis B virus; NT, non-traveller; OT, occasional traveller; FT, frequent traveller; 5EU,
NHWS, National Health and Wellness Survey; ANOVA, analysis of variance; GPs, general practitioners;
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222 R. Pedersini et al.Conclusion: Travel frequency and destination endemicity are associated with increased
hepatitis A and B vaccination. The number of unvaccinated travellers and the lack of recall
for the dosing schedule suggest the need to improve travellers’ awareness and adherence
to recommendations.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Europe is currently the world’s largest source of interna-
tional travellers [1,2]. Travel can increase risk of exposure
to infections that can be vaccine-preventable, including
hepatitis A (HAV) and hepatitis B (HBV), and many European
travellers go to HAV or HBV endemic countries [3].
Approximately 1.5 million new clinical cases of HAV
occur each year worldwide, with the incidence of infec-
tion as much as ten times higher than the number of re-
ported clinical cases [4e6]. HAV is transmitted by
ingestion of contaminated food or water and by person-
to-person exposure through the faecal-oral route. In
countries of low endemicity such as European Union (EU)
countries, the main causes of HAV infections and clinical
cases are travel to endemic countries [7e9] and import of
contaminated food [10e12], both of which may result in
outbreaks.
HBV is transmitted via percutaneous (i.e. puncture
through the skin) or mucosal contact with infectious blood
or body fluids [13,14]; 4.5 million new HBV infections and
620,000 HBV-related deaths occur each year worldwide
[15].
1.1. Signs and symptoms of infection
HAV infections do not cause chronic liver disease and are
often asymptomatic, especially in young children. Howev-
er, the disease can be severe in adolescents and adults, and
can cause debilitating symptoms [16,17]. HAV symptoms
may persist for several weeks and, with greater severity in
adults, and up to 15% of patients may experience relapsing
illness up to six months [18]. Although rare, some patients
may experience acute liver failure and in persons above 50
years old, the estimated case fatality rate can be up to 2.7%
[7,19].
HBV can cause a potentially life-threatening liver
infection, and the virus spreads through perinatal trans-
mission, horizontal transmission, percutaneous or
mucosal exposure to infected blood and body fluids, and
sexual transmission [20,21]. HBV infection ranges from
asymptomatic or mild disease and can lead to a wide
spectrum of liver disease from fulminant hepatitis and
acute liver failure to chronic hepatitis, cirrhosis, and
hepatocellular carcinoma. HBV is more severe among
adults aged >60 and is a common cause of liver disease
and liver cancer. Most adults infected with the virus
recover, but 5%e10% are unable to clear the virus and
become chronically infected and therefore can infect
others [22]. Approximately 50% of liver cancers are
attributable to HBV [23].1.2. Vaccines for HAV and HBV
HAV vaccines available in Europe are manufactured from
inactivated virus and administered via intramuscular in-
jection. For travellers, the first injection is administered
before departure and provides protection during the trip,
and a booster administered 6 months later, provides im-
munity for decades [24]. There are several monovalent HAV
vaccines produced by different companies. There is also a
combination HAV/HBV vaccine, and a vaccine combining
HAV and typhoid.
Vaccines for HBV include monovalent versions, the HAV/
HBV combination vaccine, and a heptavalent vaccine also
including diphtheria, tetanus, pertussis, and haemophilus
influenzae type b used in childhood vaccination. These
vaccines are also given through intramuscular injection. The
standard schedule includes three injections over six months.
1.3. HAV & HBV vaccination programs in Europe
The World Health Organization recommends vaccination for
HAV prior to travel to countries with moderate or higher
endemicity [16,25,26]. A few regions in Europe include HAV
vaccination in their standard childhood immunization
schedules, notably the Catalonia region of Spain [27] and
the region of Puglia in Italy [28], but vaccination against
HAV is typically not included in standard vaccination
schedules in Europe.
Universal mass vaccination programs (UMV) are common
for HBV, and so today’s adolescents and young adults in
France, Germany, Italy, and Spain have developed immu-
nity through the normal childhood vaccination schedule
[29e32]. However, these programs were initiated too
recently to have an impact on healthy adults in Europe born
before 1984, as the first significant European UMV programs
for HBV began in Italy and Catalonia for children aged 12
years in 1991.
1.4. Travel and vaccination
Previous research has found that travel is associated with
increased risk of HAV and HBV transmission [33e38]. In-
ternational travel is a major cause of HAV infection among
Europeans, even for travellers who limit themselves to
standard tourist facilities [37]. Moreover, travel duration,
underlying health conditions, and the prevalence at the
destination country have been positively associated with
HBV transmission [33,39]. Numerous studies have found
that travellers lack adequate knowledge of the risk of
infection and 33e49% of them are exposed to high-risk
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and sexual contact, often unplanned [40e44]. Despite the
potential for exposure to HAV or HBV, many travellers
remain unvaccinated. For example, the overall proportion
of HAV immune travellers going outside of Europe diverges
from different studies: 75% among Danish travellers [45],
66% in the Johannesburg Airport survey [46], 40% in the
Swedish Airport Survey [47] and 22% in the European Airport
Survey [48]. Understanding of the relationship between
travel and vaccination is limited because prior studies have
tended to sample from travel clinics or airports, which
would reflect travellers rather than the general public.
Indeed, such studies might not use the best methodological
approach to assess differences in coverage by travel fre-
quency or other traveller characteristics as a non-travelling
comparison group cannot be sampled from the same
source. While vaccination coverage of HAV and HBV among
travellers has been assessed utilizing nationally represen-
tative samples in the US, studies with similar methodologies
have not, to the authors’ knowledge, been conducted in
the EU [49,50]. Airport surveys have addressed this question
and have the strength of specifically targeting travellers
and not being biased towards those who are attending
clinics [48,51e56], though may over-represent frequent
travellers. Such studies are also limited to air travellers of
one or two national airports, not necessarily capturing
travel between Europe and HAV/HBV-endemic areas, which
may also be via rail or water.
1.5. Objective
The objective of the current study was to assess the rela-
tionship between international travel and vaccination for
HAV and HBV among adults in five of the most-populous
European countries (5EU).
2. Materials
2.1. Data source
Potential respondents were identified from the 62,000
participants in 2013 in the 5EU National Health and Well-
ness Survey (NHWS; Kantar Health, New York, USA) [57], a
cross-sectional survey representative of the total adult
populations in each of the 5 most-populous EU countries
(France, Germany, Italy, Spain and UK) drawn from Internet
survey panels with a total of 2 million panellists across
those countries. The sample in each country was not pro-
portional to the total population of each country, however,
with 15,000 respondents each in France, Germany, and the
UK, 10,000 in Italy and 7000 in Spain. The inclusion criteria
of the NHWS are as follows: 1) residence in France, Ger-
many, Italy, Spain, or the UK; 2) age 18 years; 3) literacy
in French, German, Italian, Spanish, or English; 4) provision
of informed consent.
2.2. Sample
A sample of 2102 individuals (Fig. 1) who reported HAV and
HBV status in the NHWS were re-contacted for additionalquestions on travel behaviours such as frequency, type of
travel, and vaccination status. The rate of vaccination for
HAV and HBV in the general population would limit power to
detect relationships between respondent characteristics and
vaccination status, so the sample plan incorporated receipt
of a hepatitis vaccine according to the question “Have you
ever received any of the following vaccinations?” in NHWS,
with half of the sample having indicated at least one of the
relevant options (“Hepatitis A vaccine”, “Hepatitis B vac-
cine” or “Hepatitis A/Hepatitis B combination vaccine”) and
the other half indicating none of those options, thus over-
sampling vaccinated respondents. Sampling was further
stratified within the respondents available for re-contact by
country, age, and gender to ensure a broad representation of
the population. The questionnaire took approximately
10e15 min to complete and was approved by Essex Institu-
tional Review Board (Lebanon, New Jersey, USA).
2.3. Measures
Traveller status. Respondents were asked: “How often do
you travel internationally for work or personal reasons?” and
given the following choices to select from: “more than twice
per month”, “twice a month”, “once a month”, “once every
2e3months”, “once every 4e6months”, “once a year or less
frequently”, “have never travelled internationally”.
Respondents were grouped into one of three categories
based on reported frequency of international travel.
 Non-travellers (NT) reported never travelling
internationally
 Occasional travellers (OT) reported travelling interna-
tionally once per year or less
 Frequent travellers (FT) reported travelling interna-
tionally at least twice per year
Travel-related risk. Respondents who travelled to one or
more countries at risk for HAV or HBV, or planned to travel
to those countries in the next 12 months were considered to
have travel-related risk. At-risk countries for HAV and HBV
were those with high, intermediate, or low prevalence of
HAV (Fig. 2) and HBV (Fig. 3), respectively. Non-risk coun-
tries were those with very low prevalence (Figs. 2 and 3).
Non-travel related risk. Respondents who reported any
of the following were considered to have non-travel related
risk: chronic liver disease, HIV/AIDS, diabetes (type 1 or 2),
haemophilia (treated with clotting factor concentrates),
any other illness in need of immunosuppressive therapy,
occupational exposure to human blood or blood-
contaminated body fluids, household contact with some-
one who has HAV or HBV infection.
Vaccination status. Respondents who reported being
vaccinated for HAV, HBV or HAV/HBV combination in the 10
years prior to the time of survey were considered vacci-
nated. Those who indicated they were not vaccinated, or
did not know their vaccination status were considered un-
vaccinated. Those who had been vaccinated >10 years ago
were included in the no/don’t know category for the pur-
pose of analysis.
Those who did not report being vaccinated but were part
of a UMV program were also considered vaccinated. Mass
Figure 1 Respondent flow diagram.
Figure 2 Prevalence of HAV by country.
Footnote: Source: Adapted from Centers for Disease Control and Prevention. CDC Health Information for International Travel 2014.
New York: Oxford University Press; 2014.
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Figure 3 Prevalence of HBV by country.
Footnote: Source: Adapted from Centers for Disease Control and Prevention. CDC Health Information for International Travel 2014.
New York: Oxford University Press; 2014.
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younger in 1991 and residents of Catalonia 12 years old or
younger in 1998. UMV for HBV covers residents of Italy or
Catalonia 12 years old or younger in 1991 and residents of
Spain 14 years old or younger in 1996.
Compliance. Respondents who reported having been
vaccinated for HAV or HBV in the past 12 months were asked
how many injections are needed to complete the series and
how many they had received at the time of the survey.
Covariates. Respondents also provided sociodemo-
graphic information, including age, gender, country, in-
come, etc., as well as information about their general
health, including healthcare resource use and comorbid-
ities summarized by the Charlson comorbidity index (CCI)
[58].
2.4. Analyses
Respondents were compared according to travel status (FT,
OT, NT) using chi-squared tests for categorical variables
and one-way analysis of variance (ANOVA) for continuous
variables. All variables which were found to be significant in
the bivariate analyses, and/or were of theoretical interest
as potential predictors of vaccination status, were included
in two logistic regression models, assessing the likelihood ofbeing vaccinated for HAV and HBV. Respondents eligible for
UMV programs were excluded.
3. Results
3.1. Sample description
A total of 2102 respondents completed the survey. De-
mographic characteristics by frequency of travel are pre-
sented in Table 1. Consistent with the 5EU NHWS, the
sample came primarily from France (n Z 491; 23%), Ger-
many (n Z 724; 34%), and the UK (n Z 507; 24%). Most
respondents were OT (n Z 1282; 61%). FT respondents
tended to be employed, older, and male, with higher ed-
ucation and income as compared to the OT and NT re-
spondents (all p < .05).
3.2. Vaccination rates and risk factors
Vaccination rates and the rates of risk factors are presented
in Fig. 4. Approximately half of the FTs were vaccinated for
HAV and HBV. FTs were vaccinated at significantly higher
rates, and were significantly more likely to report risk
factors for HAV or HBV compared with the other groups (all
Table 1 Demographic characteristics by frequency of international travel.
Non-traveller
(N Z 326)
Occasional traveller
(N Z 1282)
Frequent traveller
(N Z 494)
Total
(N Z 2102)
n % n % n % n % P-value
Male 118 36.20 579 45.16 284 57.49 981 46.67 <0.001
Country of residence <0.001
France 107 32.82 317 24.73 67 13.56 491 23.36
Germany 74 22.70 456 35.57 194 39.27 724 34.44
Italy 34 10.43 104 8.11 67 13.56 205 9.75
Spain 21 6.44 115 8.97 39 7.89 175 8.33
UK 90 27.61 290 22.62 127 25.71 507 24.12
Age categories 0.038
18e44 yo 205 62.88 707 55.15 280 56.6 1192 56.71
45e64 yo 100 30.67 426 33.23 165 33.40 691 32.87
65þ yo 21 6.44 149 11.62 49 9.92 219 10.42
Married/living with partner 195 59.82 764 59.59 317 64.17 1276 60.70 0.196
University degree 102 31.29 596 46.49 286 57.89 984 46.81 <0.001
Annual household income (V or £) <0.001
Less than 20k 144 44.17 314 24.49 76 15.38 534 25.40
20e40k 115 35.28 452 35.26 136 27.53 703 33.44
40e75k 28 8.59 279 21.76 184 37.25 491 23.36
75k or more 4 1.23 64 4.99 48 9.72 116 5.5
Decline to answer 35 10.74 173 13.49 50 10.12 258 12.27
Employed 188 57.67 811 63.26 377 76.32 1376 65.46 <0.001
Health insurance <0.001
Public 222 68.10 868 67.71 329 66.60 1419 67.51
Private 54 16.56 232 18.10 83 16.80 369 17.55
Public with additional
private
7 2.15 98 7.64 48 9.72 153 7.28
Other/not sure 43 13.19 84 6.55 34 6.88 161 7.66
BMI Categories 0.004
Underweight 14 4.29 45 3.51 21 4.25 80 3.81
Normal range 137 42.02 600 46.80 239 48.38 976 46.43
Overweight 87 26.69 388 30.27 149 30.16 624 29.69
Obese 77 23.62 221 17.24 64 12.96 362 17.22
Decline to answer 11 3.37 28 2.18 21 4.25 60 2.85
Exercise (once or
more per month)
170 52.15 800 62.40 380 76.92 1350 64.22 <0.001
Drink alcohol (once or
more per month)
225 69.02 1025 79.95 427 86.44 1677 79.78 <0.001
Smoke 106 32.52 317 24.73 163 33.00 586 27.88 <0.001
P-values for comparisons between frequencies are from chi-square test; p-values for comparisons between means are from ANOVA.
226 R. Pedersini et al.p < .05). Further information on vaccination and risk fac-
tors is presented in Table 2. Across all types of respondents,
approximately half of those vaccinated were either un-
certain about, or incorrectly identified, the number of in-
jections required to complete the series.
3.3. Predictors of vaccination status
Regression models predicting vaccination status indicated
higher adjusted odds of vaccination with frequent travel
and HAV/HBV risk factors (Table 3). Travel and risk were the
main factors associated with significantly higher adjusted
odds of being vaccinated in both models. In particular,
frequent traveller status was associated with 2.3e2.4 times
the odds of being vaccinated relative to non-travellers,travel-related risk was associated with 2.5e3.1 times the
odds of being vaccinated relative to those without travel to
HAV/HBV endemic areas, and non-travel-related risk was
associated with 2.1e2.9 times the odds of being vaccinated
relative to those without non-travel-related risk factors (all
p < .05). Furthermore, older age was associated with
significantly lower odds of vaccination, as was respondents’
country of residence, with Germans having the highest
adjusted odds of vaccination for HAV, followed by British
and Spanish respondents (all p < .05).
4. Discussion
The current study assessed the relationship between in-
ternational travel and vaccination for HAV and HBV among
Figure 4 Vaccination rates and risk of HAV & HBV by frequency of travel.
Footnote: Rates should not be interpreted as population vaccination rates for travel types due to inclusion of reported vaccination
for HAV and/or HBV in sampling plan. HAV Z Hepatitis A virus; HBV Z Hepatitis B virus.
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ellers and non-travellers. This study provides new infor-
mation on the relationship between travel and vaccination,
demonstrating that higher frequency of international travel
is associated with higher odds of vaccination. The results
also complement those of previous studies which used
convenience samples recruited from travel clinics or air-
ports [56].
The current study results also suggest that individuals
are sensitive to their risk status, as higher-risk individuals
were vaccinated at higher rates; adjusted odds of vacci-
nation were 2e3 times greater depending on vaccine and
type of risk. These findings corroborate prior research
which found higher protection rates among travellers to
high-risk countries than those travelling to low-risk coun-
tries [56].
The results also confirmed prior research about the lack
of knowledge among travellers [40e43], and the current
study found that many individuals could not correctly
identify the recommended vaccination schedule or recall
their vaccination history, indicating potential non-
adherence and lack of proper health care provider consul-
tation, which could result in susceptibility to infection
while travelling. Moreover, only half of frequent travellers
had been vaccinated for HAV and HBV, with many at-risk
individuals remaining unvaccinated. These findings are in
agreement with the European airport survey where 58.4%
and 68.7% of travellers could not report any protection
against HAV and HBV, respectively [48]. Moreover, these
results suggest that HBV protection coverage is similar to
previous reports from the United States (50.5% of high-risk
travellers) [50] while HAV protection was substantially
lower (26.6% of high-risk travellers) [49].The UMV programs have ensured that young people are
vaccinated for HBV, and it is estimated that the third-dose
HBV coverage (i.e. completing the third, final dose of the
HBV vaccine) has increased from 40% in 2000 to 76% in 2010
in the European region [59]. However, universal vaccination
for HAV has not been widely adopted. Even though the
vaccination for HAV and HBVdas well as improvement in
sanitation preventing transmission of HAVdhave substan-
tially decreased the incidence of HAV and HBV globally
[60e62], the incidence in some industrialized nations has
persisted due to population migration [63], import of HAV-
contaminated food [63], and to behaviours or activities that
increase the risk of exposure [33,34,63]. Furthermore,
travellers who are infected with HAV or HBV abroad may
spread the infection upon their return [3]. In many coun-
tries vaccination against HBV and, to a lesser extent, HAV is
recommended for individuals at increased risk of exposure
due to activity or behaviour, such as healthcare providers,
injection drug users, men who have sex with other men,
and travellers to endemic zones, or those with specific
conditions, including persons with human immunodefi-
ciency virus infection, end-stage renal disease, chronic
liver disease, compromised immunity [21], and diabetes
mellitus [64]. Incorporating HAV vaccination into routine
childhood immunization schedules may contribute to
reduce the incidence of HAV, as it has been demonstrated
by the HAV vaccination programmes in the US and some
European countries [65,66].
As individuals are commonly unvaccinated or unsure of
vaccination status, yet also more likely to vaccinate when
they travel frequently, to high-endemicity countries, or
are at risk for other reasons, better coverage may be
facilitated by tools which inform people of vaccine
Table 2 Risk and vaccination behaviour by travel status.
Non-traveller
(N Z 326)
Occasional traveller
(N Z 1282)
Frequent traveller
(N Z 494)
Total
(N Z 2102)
P-value
n % n % n % n %
Non-travel related risk of HAV or HBV 43 13.19 201 15.68 118 23.89 362 17.22 <0.001
Travel-related risk of HAV or HBV 17 5.21 627 48.91 401 81.17 1045 49.71 <0.001
Vaccinated for HAV <0.001
No or Don’t know 291 89.26 1061 82.76 266 53.85 1618 76.97
Yes 33 10.12 216 16.85 227 45.9 476 22.65
No, but eligible for UMV 2 0.61 5 0.39 1 0.20 8 0.38
Vaccinated for HBV <0.001
No or Don’t know 266 81.60 957 74.65 243 49.19 1466 69.74
Yes 43 13.19 276 21.53 238 48.18 557 26.50
No, but eligible for UMV 17 5.21 49 3.82 13 2.63 79 3.76
Know the correct# of injections for HAV and/or HBV 0.064
No or Don’t know 12 52.17 68 42.24 106 54.64 186 49.21
Yes 11 47.83 93 57.76 88 45.36 192 50.79
Vaccinated for other travel-related vaccine in prior 10 years <0.001
No or Don’t know 292 89.57 898 70.05 238 48.18 292 89.57
Yes 34 10.43 384 29.95 256 51.82 34 10.43
HAVZHepatitis A virus; HBVZHepatitis B virus. P-values from chi-square test. Travel-related risk is intended as travelling to a country
at risk for HAV or HBV, while non-travel related risk is identified as having chronic liver disease, HIV/AIDS, diabetes (type 1 or 2),
haemophilia (treated with clotting factor concentrates), any other illness in need of immunosuppressive therapy, occupational exposure
to human blood or blood-contaminated body fluids, or household contact with someone who has HAV/HBV infection. UMV: Universal
mass vaccination program. Other travel-related vaccines include Japanese encephalitis vaccine, typhoid vaccine, and yellow fever
vaccine. Rates should not be interpreted as population vaccination rates for travel types due to inclusion of reported vaccination for HAV
and/or HBV in sampling plan.
228 R. Pedersini et al.recommendations and their vaccination status. Vaccina-
tion registries, electronic records and portals to facilitate
access to vaccination records, as well as integration of
travel discussions into routine care may help to prevent
Europeans from acquiring HAV/HBV infections while trav-
elling abroad and transmitting the infection to others upon
their return.
4.1. Limitations
Because of the self-reported nature of the study measures,
respondents may have incorrectly reported their vaccina-
tion status which may have biased the results. Moreover,
although care was taken to include all potentially relevant
variables in the models predicting vaccination status, un-
measured variables may account for some of the relation-
ship between travel and vaccination status. Furthermore,
because of the study recruitment quota (half of the sample
had to be vaccinated for either HAV or HBV at any point in
their life), the observed vaccination rates do not reflect
vaccination rates in the general European population. The
difficulty to extrapolate and the external validity of the
findings are indeed another source of bias inherent to these
types of studies.
Finally, there was a lack of information about the
duration of travel to endemic areas. The analysis incorpo-
rated whether the destination was endemic for HAV or HBV,
but not the length of time spent at the destination. The risk
of exposure to either disease increases with length of stay,
as individuals have more opportunity to be exposed toHAV-contaminated food or water, or engage in behaviour
that may expose them to HBV.
4.2. Potential interventions
The lack of awareness of vaccination status observed in the
current study suggests a need for tools to improve traveller
awareness of the potential risks associated with travel as
well as steps to minimize these risks. Tools that can inform
travellers of their vaccination status and recommended
vaccination schedules, such as patient portals, as well as
electronic records and immunization registries to allow in-
dividuals to obtain and view their vaccination history, may
help prevent infection of individuals and potential out-
breaks upon their return.
Incorporating discussion of travel-associated risks and
vaccination status into routine healthcare may facilitate
better vaccination coverage among those most at risk for
infection for travel-related diseases. GPs (General Practi-
tioners) in particular may contribute to population health
through asking about recent travel and upcoming travel
during preventative care visits, providing an opportunity to
discuss whether a destination is endemic for HAV, HBV, and
other travel-related diseases. Such a discussion would allow
for review of vaccination records, referral to a travel health
clinic, and discussion of steps that can be taken to reduce
the risk of infection while travelling during a certain period
of time and to minimize transmission upon their return. For
example, a study in German travellers returning from Kenya
and Senegal showed that those who had used correct
Table 3 Logistic regression models: Factors affecting the likelihood of being vaccinated for HAV/HBV.
Vaccinated for HAV Vaccinated for HBV
OR [SE]b OR [SE]b
Gender
Female (reference) (reference)
Male 1.321 [0.163]* 1.058 [0.125]
Older age 0.982 [0.005]*** 0.980 [0.004]***
Higher BMI 0.984 [0.011] 0.990 [0.010]
Travelling status
Non-traveller (reference) (reference)
Occasional traveller 0.890 [0.201] 1.054 [0.213]
Frequent traveller 2.324 [0.577]*** 2.484 [0.573]***
Travel to country at risk for HAV/HBVa
No (reference) (reference)
Yes 3.084 [0.432]*** 2.432 [0.312]***
At risk for HAV/HBV (non-travel related)
No (reference) (reference)
Yes 2.062 [0.298]*** 2.899 [0.402]***
Married/living with partner
No (reference) (reference)
Yes 0.980 [0.130] 0.938 [0.120]
Education level
Up to secondary school (reference) (reference)
College/University 1.121 [0.142] 1.094 [0.133]
Annual household income (V or £)
Less than 20k (reference) (reference)
20e40k 0.811 [0.140] 0.890 [0.146]
40e75k 1.067 [0.201] 1.078 [0.196]
75k or more 1.314 [0.348] 1.060 [0.282]
Decline to answer 1.039 [0.224] 1.281 [0.264]
Employed full time/part time/self employed
No (reference) (reference)
Yes 1.057 [0.146] 1.051 [0.139]
Health insurance
National/public (reference) (reference)
Private 1.474 [0.262]* 1.163 [0.195]
Public with additional private 0.760 [0.173] 0.709 [0.160]
Other/not sure 0.943 [0.246] 0.592 [0.159]
Country of residence
France (reference) (reference)
Germany 3.851 [0.812]*** 1.734 [0.314]**
UK 2.791 [0.586]*** 1.708 [0.304]**
Italy 1.575 [0.408] 0.756 [0.207]
Spain 2.046 [0.540]** 0.924 [0.250]
Observations 2038 1938
Chi-squared 355.9 299.7
P <0.001 <0.001
Pseudo R-square 0.164 0.134
*p < 0.05; **p < 0.01; ***p < 0.001.
Respondents eligible for mass vaccination have been excluded.
HAVZHepatitis A virus; HBVZHepatitis B virus.
a Countries at risk for HAV only were included in the first regression and countries at risk for HBV only in the second regression.
b Odds ratios (OR) and standard errors (SE) are reported for each independent variable.
HAV & HBV vaccination among travellers participating in the NHWS 229malaria chemoprophylaxis were those who had received
advice from medical professionals [67]. Thus, travellers
should be made aware of the importance of seeking pre-
travel health advice. The need for awareness andcompliance to the recommended travel health advice has
been also documented in airport surveys in South Africa and
Europe, that looked at the travel-related infectious dis-
eases [46,48].
230 R. Pedersini et al.5. Conclusions
The results of this study confirm that higher frequency of
international travel and destination endemicity are asso-
ciated with higher odds of vaccination. However the fact
that many individuals were unvaccinated and around half of
the vaccinated were not able to identify the recommended
vaccination schedule or recall their vaccination history,
suggests the need for tools to improve awareness and
compliance among travellers to risk destinations.
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